Radiopharmaceuticals

NorthStar Medical Radioisotopes and Convergent Therapeutics Announce Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)

03/16/2022

− NorthStar’s high purity non-carrier-added (n.c.a.) Ac-225 to be used in Convergent’s lead, dual-targeted radionuclide program for prostate cancer, CONV01-α − Excerpt from the Press Release: BELOIT, Wis. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and Convergent Therapeutics, Inc., a…

Read More

NANOBIOTIX Announces Positive New Pre-clinical Data Suggesting Radioenhancer NBTXR3 Could Have a Significant Impact in Immunotherapy

11/22/2020

Excerpt from the Press Release: PARIS & CAMBRIDGE, Mass.–(BUSINESS WIRE)–NANOBOTIX (Euronext: NANO – ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced positive new in vivo pre-clinical data from two (2) studies at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting. One…

Read More